Impact of Octreotide on Early Complications After Liver Transplant: A Randomized, Double-Blind Placebo-Controlled Trial

被引:1
|
作者
Lankarani, Kamran Bagheri [1 ]
Safa, Hoda [2 ,4 ]
Ghahramani, Sulmaz [1 ]
Sayari, Mohammad [1 ]
Malekhosseini, Seyed-Ali [3 ]
机构
[1] Shiraz Univ Med Sci, Inst Hlth, Hlth Policy Res Ctr, Shiraz, Iran
[2] Shiraz Univ Med Sci, Dept Gastroenterol, Shiraz, Iran
[3] Shiraz Univ Sci, Shiraz Transplant Res Ctr, Shiraz, Iran
[4] Hormozgan Univ Med Sci, Dept Gastroenterol, Bandar Abbas, Iran
关键词
Acute kidney injury; Early allograft dysfunction; Length of hospital stay; Nosocomial infection; Somatostatin analog; EARLY ALLOGRAFT DYSFUNCTION; ISCHEMIA-REPERFUSION INJURY; RENAL-FUNCTION; HYPERTENSION; DEFINITION; VALIDATION; BAICALIN;
D O I
10.6002/ect.2022.0080
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Objectives: Acute kidney injury and early allograft dysfunction are 2 common complications after liver transplant. Octreotide, through its various mechanisms, may have a role in preventing these complications.Materials and Methods: In this randomized, double-blind placebo-controlled clinical trial, we randomly assigned 50 patients who underwent deceased donor liver transplant and fulfilled the study inclusion requirements to receive either octreotide infusion for 3 days in the first 3 days after transplant in the intensive care unit or placebo. The eligible patients were properly informed while on the transplant wait list and gave their consent to participate in the study. The rates of acute kidney injury within the first 7 days after transplant (based on KDIGO criteria), early allograft dysfunction, and nosocomial infection; total length of hospital stays and intensive care unit admissions; and intubation time were recorded and compared between the 2 groups.Results: No significant differences were found between the 2 groups with regard to demographic charac-teristics and graft factors (P > .05). However, acute kidney injury, early allograft dysfunction, and nosocomial infection rates were significantly lower in the octreotide group compared with the control group (P < .05). Moreover, a significant difference was observed between the 2 groups with regard to length of hospital stay and intensive care unit admissions (P < .05). For infection, female patients had a higher likelihood of infection than male patients (odds ratio = 23.19). Intensive care unit admission was associated with a higher probability of early graft dysfunction (odds ratio = 1.34). In contrast, longer intubation time was associated with a decrease in the probability of early graft dysfunction (odds ratio = 0.93).Conclusions: This study showed that octreotide infusion in the first 3 days after liver transplant could improve renal and allograft function and reduce infection and length of hospital stay.
引用
收藏
页码:835 / 841
页数:7
相关论文
共 50 条
  • [21] A randomized, double-blind, placebo-controlled trial: Paroxetine controlled release in fibromyalgia
    Patkar, AA
    Masand, PS
    Jiang, W
    Krulewicz, S
    Dube, E
    Purcell, C
    McMorran, C
    Peindl, K
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S319 - S320
  • [22] Zoledronic acid prevents bone loss after liver transplantation - A randomized, double-blind, placebo-controlled trial
    Crawford, BAL
    Kam, C
    Pavlovic, J
    Byth, K
    Handelsman, DJ
    Angus, PW
    McCaughan, GW
    ANNALS OF INTERNAL MEDICINE, 2006, 144 (04) : 239 - 248
  • [23] A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
    Turner, R. Scott
    Thomas, Ronald G.
    Craft, Suzanne
    van Dyck, Christopher H.
    Mintzer, Jacobo
    Reynolds, Brigid A.
    Brewer, James B.
    Rissman, Robert A.
    Raman, Rema
    Aisen, Paul S.
    NEUROLOGY, 2015, 85 (16) : 1383 - 1391
  • [24] Lansoprazole in Globus Pharyngeus: Double-Blind, Randomized, Placebo-Controlled Trial
    Dumper, Jaymi
    Mechor, Brad
    Chau, Jason
    Allegretto, Michael
    JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2008, 37 (05): : 657 - 663
  • [25] Pentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial
    Levin, B
    Thompson, JLP
    Levy, G
    Mitsumoto, H
    Kaufmann, P
    NEUROLOGY, 2006, 66 (11) : 1786 - 1786
  • [26] Alendronate in primary hyperparathyroidism: A double-blind, randomized, placebo-controlled trial
    Khan, AA
    Bilezikian, JP
    Kung, AWC
    Ahmed, MM
    Dubois, SJ
    Ho, AYY
    Schussheim, D
    Rubin, MR
    Shaikh, AM
    Silverberg, SJ
    Standish, TI
    Syed, Z
    Syed, ZA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (07): : 3319 - 3325
  • [27] DEXAMETHASONE FOR THE TREATMENT OF DEPRESSION - A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL
    ARANA, GW
    SANTOS, AB
    LARAIA, MT
    MCLEODBRYANT, S
    BEALE, MD
    RAMES, LJ
    ROBERTS, JM
    DIAS, JK
    MOLLOY, M
    AMERICAN JOURNAL OF PSYCHIATRY, 1995, 152 (02): : 265 - 267
  • [28] Fluoxetine for depression in diabetes - A randomized double-blind placebo-controlled trial
    Lustman, PJ
    Freedland, KE
    Griffith, LS
    Clouse, RE
    DIABETES CARE, 2000, 23 (05) : 618 - 623
  • [29] Donepezil for cancer fatigue: A double-blind, randomized, placebo-controlled trial
    Bruera, Eduardo
    El Osta, Badi
    Valero, Vicente
    Driver, Larry C.
    Pei, Be-Lian
    Shen, Loren
    Poulter, Valerie A.
    Palmer, J. Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3475 - 3481
  • [30] Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy
    Stan, Marius N.
    Garrity, James A.
    Bradley, Elizabeth A.
    Woog, John J.
    Bahn, Mark M.
    Brennan, Michael D.
    Bryant, Sandra C.
    Achenbach, Sara J.
    Bahn, Rebecca S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (12): : 4817 - 4824